New Analysis Supports Paxlovid Use

September 22, 2022

(Axios) – Here’s one more data point to consider in the back-and-forth about Pfizer’s antiviral pill Paxlovid: A new analysis found it can meaningfully reduce COVID hospitalizations and deaths, even in those younger than 65. Why it matters: Paxlovid use surged over the summer as a tool to battle COVID, but it’s also faced concerns about contributing to COVID rebound, in which patients test positive or have symptoms days after a course of the drug is completed.  (Read More)